Esperion Therapeutics Inc. (NASDAQ: ESPR) on November 20, 2023, started off the session at the price of $1.20, soaring 2.52% from the previous trading day. During the day, the shares moved up to $1.30 and dropped to $1.15 before settling in for the closing price of $1.19. Within the past 52 weeks, ESPR’s price has moved between $0.70 and $8.87.
Annual sales at Healthcare sector company slipped by -3.19% over the past five years. The company achieved an average annual earnings per share of 43.79%. With a float of $112.56 million, this company’s outstanding shares have now reached $113.72 million.
Let’s look at the performance matrix of the company that is accounted for 199 employees. In terms of profitability, gross margin is +63.61, operating margin of -237.83, and the pretax margin is -309.58.
Esperion Therapeutics Inc. (ESPR) Insider and Institutional Ownership
Observing investor behavior towards Drug Manufacturers – Specialty & Generic industry stocks is more important than anything else. The insider ownership of Esperion Therapeutics Inc. is 1.02%, while institutional ownership is 77.72%. The most recent insider transaction that took place on Sep 20, was worth 924. In this transaction Chief Commercial Officer of this company sold 742 shares at a rate of $1.25, taking the stock ownership to the 68,318 shares. Before that another transaction happened on Aug 18, when Company’s Chief Commercial Officer sold 243 for $1.41, making the entire transaction worth $344. This insider now owns 69,060 shares in total.
Esperion Therapeutics Inc. (ESPR) Latest Financial update
As on 9/29/2023, Multinational firm has announced its last quarter scores, in which it reported -$0.37 earnings per share (EPS) for the period topping the consensus outlook (set at -$0.43) by $0.06. This company achieved a net margin of -309.58. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.39 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 43.79% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 16.90% during the next five years compared to 12.80% growth over the previous five years of trading.
Esperion Therapeutics Inc. (NASDAQ: ESPR) Trading Performance Indicators
Esperion Therapeutics Inc. (ESPR) is currently performing well based on its current performance indicators. A quick ratio of 1.21 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.35.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.37, a number that is poised to hit -0.43 in the next quarter and is forecasted to reach -0.03 in one year’s time.
Technical Analysis of Esperion Therapeutics Inc. (ESPR)
Esperion Therapeutics Inc. (NASDAQ: ESPR) saw its 5-day average volume 4.04 million, a positive change from its year-to-date volume of 3.32 million. As of the previous 9 days, the stock’s Stochastic %D was 64.91%. Additionally, its Average True Range was 0.12.
During the past 100 days, Esperion Therapeutics Inc.’s (ESPR) raw stochastic average was set at 40.31%, which indicates a significant decrease from 77.35% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 113.05% in the past 14 days, which was higher than the 91.60% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.9847, while its 200-day Moving Average is $1.8932. Nevertheless, the first resistance level for the watch stands at $1.2967 in the near term. At $1.3733, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.4467. If the price goes on to break the first support level at $1.1467, it is likely to go to the next support level at $1.0733. The third support level lies at $0.9967 if the price breaches the second support level.
Esperion Therapeutics Inc. (NASDAQ: ESPR) Key Stats
Market capitalization of the company is 138.74 million based on 113,718K outstanding shares. Right now, sales total 75,480 K and income totals -233,660 K. The company made 33,970 K in profit during its latest quarter, and -41,250 K in sales during its previous quarter.